Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004-2011
- PMID: 25894392
- PMCID: PMC6743325
- DOI: 10.1111/jvh.12414
Increase in nonhepatic diagnoses among persons with hepatitis C hospitalized for any cause, United States, 2004-2011
Abstract
Although persons with hepatitis C virus (HCV) infection may experience nonhepatic illnesses, little is known about the frequency of and trends in such conditions in a population-based sample of HCV-infected persons. Using hospitalization data collected during 2004-2011 from the Nationwide Inpatient Sample of the Healthcare Cost and Utilization Project, we examined trends in comorbidities among all hospitalizations that included either a principal or secondary HCV diagnostic code (i.e., HCV was not necessarily the cause for hospitalization). We also compared comorbidities among all persons aged 45-64 years hospitalized with and without principal or secondary HCV diagnostic codes. The estimated number of hospitalizations among persons with HCV infection increased from 850,490 in 2004-2005 to 1,178,633 in 2010-2011; mean age at hospitalization was 50 years in 2004-2005 and 52.5 years in 2010-2011. There were significant increases in the prevalence of most medical and psychiatric comorbidities; the largest were for lipid disorders, chronic kidney disease and obesity. Among HCV-infected aged 45-64 persons hospitalized for any cause, the prevalence of alcohol /substance abuse, mental disorders, chronic kidney disease, pneumonia, hepatitis B virus infection and HIV infection were significantly higher than those aged 45-64 persons hospitalized without HCV infection (P < 0.001 for all). The prevalence of cryoglobulinaemia, vasculitis, nephrotic syndrome or membranoproliferative glomerulonephritis and porphyria cutanea tarda among hospitalizations with HCV infection was consistently low during the study period (i.e., <0.5%). The increase we observed in nonhepatic comorbidities associated with a high risk of HCV-related complications has important implications for the current HCV treatment recommendations in a greatly expanded treatment population.
Keywords: healthcare cost and utilization project; international classification of diseases, 9th revision, clinical modification; morbidity; nationwide inpatient sample; treatment guidelines.
Published 2015. This article is a U.S. Government work and is in the public domain in the USA.
Conflict of interest statement
DISCLOSURES/CONFLICT OF INTEREST
None.
Similar articles
-
Temporal Trends in Hepatitis C-Related Hospitalizations, United States, 2000-2019.Clin Infect Dis. 2023 Dec 15;77(12):1668-1675. doi: 10.1093/cid/ciad425. Clin Infect Dis. 2023. PMID: 37463305
-
Increasing Prevalence of Hepatitis C among Hospitalized Children Is Associated with an Increase in Substance Abuse.J Pediatr. 2018 Jan;192:159-164. doi: 10.1016/j.jpeds.2017.09.016. Epub 2017 Nov 6. J Pediatr. 2018. PMID: 29106926
-
Dialysis-requiring acute kidney injury among hospitalized adults with documented hepatitis C Virus infection: a nationwide inpatient sample analysis.J Viral Hepat. 2016 Jan;23(1):32-8. doi: 10.1111/jvh.12437. Epub 2015 Jul 20. J Viral Hepat. 2016. PMID: 26189719 Free PMC article.
-
Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.Gastroenterology. 2016 Jun;150(7):1599-1608. doi: 10.1053/j.gastro.2016.02.039. Epub 2016 Feb 26. Gastroenterology. 2016. PMID: 26924097 Review.
-
NIH Consensus Statement on Management of Hepatitis C: 2002.NIH Consens State Sci Statements. 2002 Jun 10-12;19(3):1-46. NIH Consens State Sci Statements. 2002. PMID: 14768714 Review.
Cited by
-
Renal Manifestations of Chronic Hepatitis C: A Review.J Clin Med. 2024 Sep 18;13(18):5536. doi: 10.3390/jcm13185536. J Clin Med. 2024. PMID: 39337023 Free PMC article. Review.
-
Temporal Trends in Hepatitis C-Related Hospitalizations, United States, 2000-2019.Clin Infect Dis. 2023 Dec 15;77(12):1668-1675. doi: 10.1093/cid/ciad425. Clin Infect Dis. 2023. PMID: 37463305
-
Renal function trajectories in hepatitis C infection: differences between renal healthy and chronic kidney disease individuals.Sci Rep. 2021 Aug 25;11(1):17197. doi: 10.1038/s41598-021-96782-x. Sci Rep. 2021. PMID: 34433887 Free PMC article. Clinical Trial.
-
Association of Infection With Human Papillomavirus and Development of End-Stage Kidney Disease in Taiwan.JAMA Netw Open. 2020 Oct 1;3(10):e2022107. doi: 10.1001/jamanetworkopen.2020.22107. JAMA Netw Open. 2020. PMID: 33090225 Free PMC article.
-
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.J Viral Hepat. 2019 Jun;26(6):685-696. doi: 10.1111/jvh.13080. Epub 2019 Mar 5. J Viral Hepat. 2019. PMID: 30739368 Free PMC article.
References
-
- IOM (Institute of Medicine). Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press, 2010. - PubMed
-
- Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. N Engl J Med 1995; 123: 615–620. - PubMed
-
- Basseri B, Yamini D, Chee G et al. Comorbidities associated with the increasing burden of hepatitis C infection. Liver Int 2010; 30: 10121018. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
